http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2691535-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d657c5e1829b376e998752dc2e5caae0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d707299e3128a6bc35c468037bd0b8f4 |
| publicationDate | 2014-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2691535-A1 |
| titleOfInvention | Cancer markers |
| abstract | Hence, the invention relates to a method for diagnosis and/or prognosis of cancer, comprising the steps of analyzing in a sample of a subject the DNA methylation status of a genomic region of at least one member of the group of, (i) SFN according to SEQ ID NO. 1, (ii) SLIT2 according to SEQ ID NO. 2, (iii) SERPINB5 according to SEQ ID NO. 3; and (iv) TWIST 1 according to SEQ ID NO 4; wherein, if (i) SFN shows a methylation cut off value of above 80 % and/or, (ii) SLIT2 shows a methylation cut-off value of above 45 % and/or, (iii) SERPBINB5 shows a methylation cut-off value of above 70 %, and/or (iv) TWIST 1 shows a methylation level below 15 % the sample is categorized as a sample from a patient with cancer and/of a poor prognosis. |
| priorityDate | 2011-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.